Patient characteristics
| Parameter . | IM 400 mg . | IM 800 mg . | Second TKI . | P . |
|---|---|---|---|---|
| No. of patients treated | 73 | 208 | 154 | |
| Median age, y (range) | 48 (15-78) | 48 (17-84) | 47 (18-85) | .48 |
| Prior cytoreduction, % | 51 (73) | 95 (46) | 60 (39) | .0001 |
| Splenomegaly, % | 16 (22) | 59 (28) | 41 (27) | .56 |
| Hemoglobin, g/dL, < 12.0, no. (%) | 27 (37) | 82 (39) | 71 (46) | .32 |
| WBCs, × 109/L, ≥ 10, no. (%) | 55 (75) | 178 (86) | 112 (73) | .01 |
| Platelets, × 109/L, > 450, no. (%) | 22 (30) | 68 (33) | 43 (28) | .62 |
| Peripheral blast, %, any, no. (%) | 18 (25) | 76 (36) | 43 (28) | .09 |
| Peripheral basophils, %, ≥ 5, no. (%) | 15 (21) | 60 (29) | 39 (25) | .43 |
| Marrow blast, %, ≥ 5, no. (%) | 3 (4) | 18 (9) | 9 (6) | .40 |
| Marrow basophils, %, ≥ 5, no. (%) | 7 (10) | 32 (15) | 13 (8) | .11 |
| Sokal risk, no. (%) | ||||
| Low | 50 (68) | 132 (63) | 118 (77) | .02 |
| Intermediate | 22 (30) | 57 (27) | 27 (18) | |
| High | 1 (2) | 19 (9) | 9 (6) | |
| Ph+ > 90%, % | 67/72 (93) | 195 (94) | 133 (86) | .04 |
| Clonal evolution, % | 2 (3) | 7 (3) | 11/151 (7) | .15 |
| Parameter . | IM 400 mg . | IM 800 mg . | Second TKI . | P . |
|---|---|---|---|---|
| No. of patients treated | 73 | 208 | 154 | |
| Median age, y (range) | 48 (15-78) | 48 (17-84) | 47 (18-85) | .48 |
| Prior cytoreduction, % | 51 (73) | 95 (46) | 60 (39) | .0001 |
| Splenomegaly, % | 16 (22) | 59 (28) | 41 (27) | .56 |
| Hemoglobin, g/dL, < 12.0, no. (%) | 27 (37) | 82 (39) | 71 (46) | .32 |
| WBCs, × 109/L, ≥ 10, no. (%) | 55 (75) | 178 (86) | 112 (73) | .01 |
| Platelets, × 109/L, > 450, no. (%) | 22 (30) | 68 (33) | 43 (28) | .62 |
| Peripheral blast, %, any, no. (%) | 18 (25) | 76 (36) | 43 (28) | .09 |
| Peripheral basophils, %, ≥ 5, no. (%) | 15 (21) | 60 (29) | 39 (25) | .43 |
| Marrow blast, %, ≥ 5, no. (%) | 3 (4) | 18 (9) | 9 (6) | .40 |
| Marrow basophils, %, ≥ 5, no. (%) | 7 (10) | 32 (15) | 13 (8) | .11 |
| Sokal risk, no. (%) | ||||
| Low | 50 (68) | 132 (63) | 118 (77) | .02 |
| Intermediate | 22 (30) | 57 (27) | 27 (18) | |
| High | 1 (2) | 19 (9) | 9 (6) | |
| Ph+ > 90%, % | 67/72 (93) | 195 (94) | 133 (86) | .04 |
| Clonal evolution, % | 2 (3) | 7 (3) | 11/151 (7) | .15 |
IM indicates imatinib; and WBCs, white blood cells.